New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
16:46 EDTREGNRegeneron recommends rejection of mini-tender offer by TRC Capital
Regeneron Pharmaceuticals (REGN) has been notified of an unsolicited "mini-tender" offer by TRC Capital to purchase up to 1M shares, or approximately 1.06%, of the outstanding Regeneron common stock at a price of $161.25 per share. TRC's offer price represents approximately a 4.46% discount to the closing price of Regeneron common stock on December 27, 2012, the last closing price prior to commencement of the offer, and a 10.77% discount to the closing price of Regeneron common stock on January 3, 2013. In addition, TRC's offer is subject to numerous conditions, including the availability of financing satisfactory to TRC. Regeneron does not endorse TRC's offer and recommends that shareholders do not tender their shares in response to the offer because it is a so-called "mini-tender" offer at a price below the current market price for Regeneron shares and is subject to numerous conditions. Regeneron urges shareholders considering TRC's offer to obtain current market quotations for their shares, review the conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC's offer. Regeneron is not associated in any way with TRC, its mini-tender offer or the offer documentation. According to TRC's current offer documents, Regeneron shareholders who have tendered their shares may withdraw their shares at any time prior to 12:01 a.m., New York City time, on Tuesday, January 29, 2013, the expiration date set forth in the offer documents (unless extended), by following the procedures described in the offer documents.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:49 EDTREGNRegeneron Eylea data positive, says RBC Capital
Subscribe for More Information
February 24, 2015
07:31 EDTREGNRBC Capital to hold a conference
Subscribe for More Information
February 20, 2015
16:48 EDTREGNDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
12:07 EDTREGNEYLEA reimbursment could be influenced by UK recommendation, says Piper Jaffray
Subscribe for More Information
12:01 EDTREGNNICE recommends EYLEA for DME, but only in certain cases
Subscribe for More Information
07:08 EDTREGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:28 EDTREGNOn The Fly: Closing Wrap
Subscribe for More Information
15:58 EDTREGNRegeneron downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
10:00 EDTREGNRegeneron Praluent launch costs a concern, says Piper Jaffray
Subscribe for More Information
09:01 EDTREGNData to accelerate growth of Regeneron's Eylea, says Bernstein
Subscribe for More Information
07:28 EDTREGNRegeneron data better than expected, says RBC Capital
RBC Capital believes that Protocol-T results for Regneron's (REGN) Eylea were better than expected. The firm says that Eylea improved the vision of all patients more than Roche's treatments,and was much better than Roche's drugs in treating patients with moderate or worse vision loss. The firm keeps a $490 price target and Outperform rating on Regeneron.
06:56 EDTREGNData support Regeneron drug over competition, says Deutsche Bank
Subscribe for More Information
06:45 EDTREGNStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
February 18, 2015
17:23 EDTREGNRegeneron reports positive results for Eylea injection in diabetic macular edema
Subscribe for More Information
03:20 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
February 17, 2015
10:01 EDTREGNCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
10:00 EDTREGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Box, Inc. (BOX) initiated with a Hold at Canaccord... Euronav NV (EURN) initiated with an Overweight at Morgan Stanley... GoPro (GPRO) initiated with an Outperform at Northland... M/A-COM (MTSI) initiated with a Neutral at BofA/Merrill... Macy's (M) initiated with an Underweight at Barclays... NetSuite (N) initiated with an Underperform at Exane BNP Paribas... Omega Healthcare (OHI) initiated with a Neutral at BofA/Merrill... Pandora (P) initiated with a Neutral at Macquarie... Pattern Energy (PEGI) coverage resumed with an Outperform at BMO Capital... Regeneron (REGN) initiated with an Outperform at Bernstein... Trovagene (TROV) initiated with an Overweight at Piper Jaffray... Vista Outdoor (VSTO) initiated with a Market Perform at Cowen.
06:35 EDTREGNRegeneron initiated with an Outperform at Bernstein
Target $475.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use